ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.

Blakey, D C; Burke, P J; Davies, D H; Dowell, R I; East, S J; Eckersley, K P; Fitton, J E; McDaid, J; Melton, R G; Niculescu-Duvaz, I A; Pinder, P E; Sharma, S K; Wright, A F; Springer, C J

Blakey, D C; Burke, P J; Davies, D H; Dowell, R I; East, S J; Eckersley, K P; Fitton, J E; McDaid, J; Melton, R G; Niculescu-Duvaz, I A; Pinder, P E; Sharma, S K; Wright, A F; Springer, C J.

Affiliation

Blakey DC; Cancer, Metabolism, and Endocrine Research Department, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom.

Cancer Res ; 56(14): 3287-92, 1996 Jul 15.

Article in En | MEDLINE | ID: mdl-8764123

Subject(s)

Antineoplastic Agents, Alkylating/administration & dosage; Colorectal Neoplasms/drug therapy; Nitrogen Mustard Compounds/administration & dosage; Prodrugs/administration & dosage; Animals; Antibodies, Monoclonal/therapeutic use; Antibodies, Neoplasm/therapeutic use; Female; Humans; Immunotoxins/administration & dosage; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; gamma-Glutamyl Hydrolase/metabolism

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prodrugs / Colorectal Neoplasms / Antineoplastic Agents, Alkylating / Nitrogen Mustard Compounds Limits: Animals / Female / Humans Language: En Journal: Cancer Res Year: 1996 Document type: Article

Search on Google

XML

PubMed Links